Recro Pharma (REPH) Earns Outperform Rating from Analysts at UBS Group

Investment analysts at UBS Group began coverage on shares of Recro Pharma (NASDAQ:REPH) in a report issued on Tuesday, The Fly reports. The brokerage set an “outperform” rating on the specialty pharmaceutical company’s stock.

REPH has been the topic of several other research reports. Zacks Investment Research downgraded shares of Recro Pharma from a “buy” rating to a “hold” rating in a report on Thursday, November 16th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $11.00 price target on shares of Recro Pharma in a report on Friday, October 27th. Finally, Oppenheimer started coverage on shares of Recro Pharma in a report on Tuesday. They set a “buy” rating and a $19.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $12.88.

Shares of Recro Pharma (NASDAQ REPH) traded up $0.12 during trading hours on Tuesday, reaching $8.21. 47,621 shares of the company’s stock traded hands, compared to its average volume of 114,843. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.59 and a quick ratio of 1.35. Recro Pharma has a twelve month low of $5.81 and a twelve month high of $10.59. The stock has a market capitalization of $157.01, a P/E ratio of -3.82 and a beta of -0.60.

In other news, major shareholder Healthcare Master Fun Broadfin sold 100,000 shares of the business’s stock in a transaction on Tuesday, December 5th. The shares were sold at an average price of $10.00, for a total value of $1,000,000.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder Scp Vitalife Partners Ii Lp sold 13,189 shares of the business’s stock in a transaction on Wednesday, December 27th. The stock was sold at an average price of $9.56, for a total transaction of $126,086.84. Following the completion of the transaction, the insider now directly owns 2,243,064 shares in the company, valued at approximately $21,443,691.84. The disclosure for this sale can be found here. Insiders sold 860,414 shares of company stock worth $8,289,916 in the last three months. Insiders own 21.60% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. Wells Fargo & Company MN lifted its holdings in shares of Recro Pharma by 42.5% in the third quarter. Wells Fargo & Company MN now owns 24,508 shares of the specialty pharmaceutical company’s stock worth $220,000 after buying an additional 7,308 shares in the last quarter. Cadence Capital Management LLC increased its position in Recro Pharma by 7.8% in the fourth quarter. Cadence Capital Management LLC now owns 180,715 shares of the specialty pharmaceutical company’s stock worth $1,672,000 after purchasing an additional 13,078 shares during the last quarter. BlackRock Inc. increased its position in Recro Pharma by 1.4% in the fourth quarter. BlackRock Inc. now owns 1,011,855 shares of the specialty pharmaceutical company’s stock worth $9,359,000 after purchasing an additional 13,799 shares during the last quarter. JPMorgan Chase & Co. increased its position in Recro Pharma by 183.4% in the third quarter. JPMorgan Chase & Co. now owns 21,784 shares of the specialty pharmaceutical company’s stock worth $197,000 after purchasing an additional 14,098 shares during the last quarter. Finally, Strs Ohio increased its position in Recro Pharma by 455.0% in the fourth quarter. Strs Ohio now owns 22,200 shares of the specialty pharmaceutical company’s stock worth $205,000 after purchasing an additional 18,200 shares during the last quarter. 61.88% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: This story was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another domain, it was stolen and reposted in violation of United States & international copyright law. The original version of this story can be accessed at https://www.americanbankingnews.com/2018/02/13/recro-pharma-reph-earns-outperform-rating-from-analysts-at-ubs-group.html.

Recro Pharma Company Profile

Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.

The Fly

Analyst Recommendations for Recro Pharma (NASDAQ:REPH)

Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply